Small Cell Lung Cancer

SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC

By

Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

Adding Vandetanib to Platinum + Etoposide Not Effective for SCLC

By

The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.

Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC

Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC

By

Surgery for early stage small cell lung cancer (SCLC) is rarely used. However, results from a population-based database has shown surgery with adjuvant chemotherapy with or without radiation for node-negative SCLC was associated with better survival compared with concurrent chemoradiation, according to a presentation at the 2016 ASCO Annual Meeting.

Adjuvant Therapy Increases Survival in Small-Cell Lung Cancer

Adjuvant Therapy Increases Survival in Small-Cell Lung Cancer

Chemotherapy, with or without cranial irradiation, has been associated with improved survival versus surgery alone for patients with early-stage small-cell lung cancer (SCLC) undergoing resection.

Chemotherapy Use Associated with Survival Benefit Among Medicare Patients with SCLC

Chemotherapy Use Associated with Survival Benefit Among Medicare Patients with SCLC

Chemotherapy use associated with a survival benefit for Medicare patients with small cell lung cancer (SCLC) treated in a real-world setting.

Chemotherapy may be underused in elderly with lung cancer

By

Chemotherapy can improve median survival by more than 6 months in elderly persons with small cell lung cancer (SCLC), a retrospective cohort study has indicated.

Lung cancer diagnosis improved by new RNA diagnostic test

By

A histology-expression predictor has been developed for the most common types of lung cancer and can corroborate the findings of pathologists.

PET improves survival in limited-stage lung cancer

By

Persons with limited-stage small cell lung cancer (LS-SCLC) exhibited better disease control and survival when staged with positron emission tomography (PET) than did patients who did not undergo staging with PET.

Denosumab extended survival in lung cancer with bone metastases

By

Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.

Breath test can indicate lung cancer

An analysis of breath samples from patients with pulmonary nodules distinguished benign from malignant growths in a recent study.

PARP inhibitors may help in small cell lung cancer

PARP1 and EZH2 may be treatment targets in small cell lung cancer, based on newfound differences between this and non-small cell disease.

Molecular Differences ID'd for Small/Non-Small Cell Lung CA

Molecular Differences ID'd for Small/Non-Small Cell Lung CA

Small cell lung cancers have high expression of PARP1; are more sensitive to PARP inhibition.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs